TuHURA Biosciences Inc 2024年度报告

(Mark One) ☒Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934For the transition period fromtoCommission File Number:001-39473 TUHURA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 ofthe Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflectthe correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any ofthe registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes☐No☒ The aggregate market value of the common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The NasdaqStock Market (“Nasdaq”) on June 30, 2024 (the last business day of the registrant’s second fiscal quarter), was $14,932,000, based on the closing price on Nasdaqreported for such date. As of March 31, 2025, there were43,680,397shares of the registrant’s common stock outstanding. Table of Contents Forward-Looking Statements PART I4Item 1. Business4Item 1A. Risk Factors43Item 1B. Unresolved Staff Comments81Item 1C. Cybersecurity81Item 2. Properties82Item 3. Legal Proceedings82Item 4. Mine Safety Disclosures82PART II82Item 5. Market for Registrant’s Common Equity; Related Stockholder Matters and Issuer Purchases of EquitySecurities82Item 6. [Reserved]82Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation83Item 7A. Quantitative and Qualitative Disclosures About Market Risk94Item 8. Financial Statements and Supplementary Data94Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure94Item 9A. Controls and Procedures94Item 9B. Other Information95Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections95PART III96Item 10. Directors, Executive Officers and Corporate Governance96Item 11. Executive Compensation100Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters109Item 13. Certain Relationships and Related Transactions, and Director Independence113Item 14. Principal Accounting Fees and Services114PART IV115Item 15. Exhibits, Financial Statement Schedules115Item 16. Form 10-K Summary118Signatures EXPLANATORY NOTE On October 18, 2024, the Nevada corporation formerly known as “Kintara Therapeutics, Inc.” completed its previouslyannounced merger transaction in accordance with the terms of the Agreement and Plan of Merger, dated as of April 2, 2024 (the“Kintara Merger Agreement”), by and among Kintara Therapeutics, Inc. (“Kintar